Lifetech Scientific (Shenzhen) Co., Ltd.

Beijing, Beijing Municipality

Oncologyliquid biopsyPhase II

Compare Sign in to watch

What changed

NIH R35 · $0.6M · Molecular Basis and Regulatory Mechanisms of Exosome Secretion

2mo agoGrant renewalApr 27, 2026Source filing (opens the source filing in a new tab)

Momentum

75no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,109 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Jan 1, 2026
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer · NOT_YET_RECRUITING · sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
ClinicalTrials.gov · NCT07376876 (opens the source filing in a new tab)
Grant
U01 · $678k · non-dilutive
Aug 20, 2025
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEAVER, VALERIE MARIE · NCI · award ends Jul 31, 2030 · Antidepressant regulation of PDAC
NIH RePORTER · NIH RePORTER 11123025 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jan 13, 2023
Esophageal Squamous Cell Carcinoma · COMPLETED · sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
ClinicalTrials.gov · NCT05880082 (opens the source filing in a new tab)
Trial
NA registered
Oct 1, 2021
Thoracoabdominal; Aortic, Aneurysm, Dissecting · RECRUITING · sponsor: Lifetech Scientific (Shenzhen) Co., Ltd. · Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.
ClinicalTrials.gov · NCT05803564 (opens the source filing in a new tab)
Grant
U01 · $673k · non-dilutive
Sep 16, 2021
UNIVERSITY OF PENNSYLVANIA · PI RADHAKRISHNAN, RAVI · NCI · award ends Aug 31, 2026 · A physical sciences approach to investigate the role of exosomes in metastatic progression
NIH RePORTER · NIH RePORTER 11169899 (opens the source filing in a new tab)
Grant
P50 · $445k · non-dilutive
Sep 3, 2021
WISTAR INSTITUTE · PI GUO, WEI · NCI · award ends Dec 31, 2026 · Targeting exosomal PDL1 to improve immunotherapy
NIH RePORTER · NIH RePORTER 11187259 (opens the source filing in a new tab)
Grant
R35 · $640k · non-dilutive
May 1, 2021
UNIVERSITY OF PENNSYLVANIA · PI GUO, WEI · NIGMS · award ends Apr 30, 2031 · Molecular Basis and Regulatory Mechanisms of Exosome Secretion
NIH RePORTER · NIH RePORTER 11259763 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 82%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator WEAVER, VALERIE MARIE is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R35 · $0.6M · Molecular Basis and Regulatory Mechanisms of Exosome Secretion
2mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
5mo agoTrial registeredSource (opens the source filing in a new tab)
NIH P50 · $0.4M · Targeting exosomal PDL1 to improve immunotherapy
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH U01 · $0.7M · A physical sciences approach to investigate the role of exosomes in metastatic progression
10mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer
10mo agoTrial completedSource (opens the source filing in a new tab)
NIH U01 · $0.7M · Antidepressant regulation of PDAC
11mo agoNew grantSource (opens the source filing in a new tab)
Study registered, no phase assigned: Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.
Jun 2025Trial recruitingSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE2 registered

U01 · $678k · non-dilutive

PHASE2 registered

NA registered

U01 · $673k · non-dilutive

P50 · $445k · non-dilutive

R35 · $640k · non-dilutive